---
document_datetime: 2026-01-09 14:08:36
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/tolvaptan-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: tolvaptan-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.2248154
conversion_datetime: 2026-01-10 10:56:42.665609
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.1
  docling: 2.67.0
  docling-core: 2.58.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Tolvaptan Accord

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                           |
|----------------------|-------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|---------------------------------------------------|
| Variation type IB /  | C.I.2 Change(s) in the Summary of Product | 09/01/2026                          |                                             | SmPC and PL                      | To update Section 4.5 of SmPC and section 2 of PL |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000317240   | Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted C.I.2.a (Type IB) - To update Section 4.5 of SmPC and section 2 of PL to add drug-drug interaction information with St John's wort, following approval of same change in reference product Samsca. In addition, the MAH took the opportunity to implement editorial changes in Sections 4.4 and 4.5 of the SmPC to align with the reference product.   | to add drug-drug interaction information with St John's wort, following approval of same change in reference product Samsca.   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------|